Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Elizabeth Geena Woo has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Genetic regulation of ALK inhibitor response in diverse human cell types

    by Elizabeth Geena Woo, Katherine L. Rhodes, Natalia M. Gonzales, Kenneth A. Barr, Emaan Mohsin, Everett E. Vokes, Yoav Gilad

    Anaplastic lymphoma kinase (ALK) inhibitors are effective treatments for ALK-positive non-small cell lung cancer but cause diverse adverse events affecting multiple tissues. Genetic variation may contribute to inter-individual differences in susceptibility, but the small number of treated patients limits the power of genetic association studies. Moreover, the diversity of affected tissues and cell types makes functional investigation challenging. We used induced pluripotent stem cells from 49 individuals to generate heterogeneous differentiating cultures (HDCs) containing multiple cell types, treated them with five ALK inhibitors (crizotinib, alectinib, ceritinib, brigatinib, and lorlatinib) for 24 hours, and characterized transcriptional responses using single-cell RNA sequencing. These responses showed cell-type-specific and shared transcriptional effects. Integrating gene expression with individual genotypes, we identified 4,371 expression quantitative trait loci (eQTLs) across 21 cell types, including 2,137 response eQTLs whose regulatory effects differ between untreated and drug-treated cells. These results nominate candidates for future studies of ALK inhibitor toxicity.

  • Open Access

    Leveraging Large Language Models to Develop an Interpretable Prediction Model for Postpartum Hemorrhage Prior to the Onset of Labor

    by Elizabeth Geena Woo, Israel Zighelboim, Tyler Gifford, Joseph G Bell, Hannah Milthorpe, Emilly Alsentzer, Ryan E Longman, Jorge E Tolosa, Brett K Beaulieu-Jones

    Objective: To evaluate whether large language models (LLMs) applied to prenatal clinical notes can predict postpartum hemorrhage (PPH) prior to the onset of labor and to compare model performance across outcome definitions, including a novel intervention-based definition. Methods: We conducted a retrospective cohort study of 19,992 deliveries within a large regional health network. Two outcome definitions for PPH were used: estimated or quantitative blood loss (EBL/QBL) extracted from clinical notes, and a clinical intervention-based definition (cPPH) incorporating transfusion, uterotonics, Bakri balloon, or hysterectomy. We evaluated three approaches for PPH prediction: (1) supervised machine learning using structured electronic medical record data; (2) direct prediction using a fine-tuned LLM applied to clinical notes; and (3) interpretable models using LLM-extracted features combined with structured data. Model performance was evaluated using area under the receiver operating characteristic curve (AUROC) on a temporally held-out test set. Results: The LLM-based direct prediction model achieved the highest performance for both PPH definitions (AUROC 0.79–0.80), followed by interpretable models combining LLM-extracted features with structured data (AUROC 0.76–0.78). Models using only structured data performed worse (AUROC 0.65–0.71). The LLM-extracted features approach identified 47 significant predictors, including established risk factors such as multiple gestation and previous cesarean delivery. Demographic differences were observed between PPH definitions: mothers who met only the cPPH definition had lower gestational age and higher rates of cesarean delivery compared to those meeting only the EBL/QBL definition. Conclusion: These findings highlight the potential of LLM-based approaches for enhancing PPH risk stratification, with the feature extraction method offering a promising balance between predictive performance and clinical utility. Integrating these methods into clinical workflows could improve early detection and guide targeted preventive interventions.


  • Open Access

    Predominant Founder Effect among Recurrent Pathogenic Variants for an X-Linked Disorder

    by Chelsea Bender, Elizabeth Geena Woo, Bin Guan, Ehsan Ullah, Eric Feng, Amy Turriff, Santa J. Tumminia, Paul A. Sieving, Catherine A. Cukras, Robert B. Hufnagel

    For disorders with X-linked inheritance, variants may be transmitted through multiple generations of carrier females before an affected male is ascertained. Pathogenic RS1 variants exclusively cause X-linked retinoschisis (XLRS). While RS1 is constrained to variation, recurrent variants are frequently observed in unrelated probands. Here, we investigate recurrent pathogenic variants to determine the relative burden of mutational hotspot and founder allele events to this phenomenon. A cohort RS1 variant analysis and standardized classification, including variant enrichment in the XLRS cohort and in RS1 functional domains, were performed on 332 unrelated XLRS probands. A total of 108 unique RS1 variants were identified. A subset of 19 recurrently observed RS1 variants were evaluated in 190 probands by a haplotype analysis, using microsatellite and single nucleotide polymorphisms. Fourteen variants had at least two probands with common variant-specific haplotypes over ~1.95 centimorgans (cM) flanking RS1. Overall, 99/190 of reportedly unrelated probands had 25 distinct shared haplotypes. Examination of this XLRS cohort for common RS1 haplotypes indicates that the founder effect plays a significant role in this disorder, including variants in mutational hotspots. This improves the accuracy of clinical variant classification and may be generalizable to other X-linked disorders.


  • Open Access

    Next-Generation Sequencing Analysis of GBA1: The Challenge of Detecting Complex Recombinant Alleles

    by Elizabeth G. Woo, Nahid Tayebi, Ellen Sidransky

    Next-Generation Sequencing Analysis of GBA1: The Challenge of Detecting Complex Recombinant Alleles


  • Open Access

    The Role of Exosomes in Lysosomal Storage Disorders

    by Adenrele M. Gleason, Elizabeth G. Woo, Cindy McKinney, Ellen Sidransky

    Exosomes, small membrane-bound organelles formed from endosomal membranes, represent a heterogenous source of biological and pathological biomarkers capturing the metabolic status of a cell. Exosomal cargo, including lipids, proteins, mRNAs, and miRNAs, can either act as inter-cellular messengers or are shuttled for autophagic/lysosomal degradation. Most cell types in the central nervous system (CNS) release exosomes, which serve as long and short distance communicators between neurons, astrocytes, oligodendrocytes, and microglia. Lysosomal storage disorders are diseases characterized by the accumulation of partially or undigested cellular waste. The exosomal content in these diseases is intrinsic to each individual disorder. Emerging research indicates that lysosomal dysfunction enhances exocytosis, and hence, in lysosomal disorders, exosomal secretion may play a role in disease pathogenesis. Furthermore, the unique properties of exosomes and their ability to carry cargo between adjacent cells and organs, and across the blood–brain barrier, make them attractive candidates for use as therapeutic delivery vehicles. Thus, understanding exosomal content and function may have utility in the treatment of specific lysosomal storage disorders. Since lysosomal dysfunction and the deficiency of at least one lysosomal enzyme, glucocerebrosidase, is associated with the development of parkinsonism, the study and use of exosomes may contribute to an improved understanding of Parkinson disease, potentially leading to new therapeutics.